{"disease":{"id":"multiple-myeloma-as-monotherapy-in-patients-who-have-received-at-least-three-prior-lines-of-therapy-including-a-proteasome-inhibitor-pi-and-an-immunomodulatory-agent-or-who-are-double-refractory-to-a-pi-and-an-immunomodulatory-agent.md","name":"multiple myeloma as monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}